Moderna Inc. (MRNA) Analysis & Opinions from Experts

Moderna Inc. (NASDAQ: MRNA) is 239.72% higher on its value in year-to-date trading and has touched a low of $13.53 and a high of $95.21 in the current 52-week trading range. The MRNA stock was last observed hovering at around $66.45 in the last trading session, with the day’s loss setting it -1.57% off its average median price target of $92.00 for the next 12 months. It is also 51.58% off the consensus price target high of $134.00 offered by analysts, but current levels are -11.86% lower than the price target low of $58.00 for the same period.

5 Stocks to make up the PERFECT 2021 gold portfolio

Gold bugs are shouting from the rooftops in excitement, but that doesn’t mean you rush out and just buy any gold stock…That’s why we laid out The 2021 Ultimate Gold Portfolio – to dissect the treasure from the trash.

Click here to download your free report right away


Currently trading at $64.88, the stock is -11.08% and -7.77% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 13.11 million and changing -2.36% at the moment leaves the stock 56.42% off its SMA200. MRNA registered 369.28% gain for a year compared to 6-month gain of 257.45%. The firm has a 50-day simple moving average (SMA 50) of $73.36 and a 200-day simple moving average (SMA200) of $51.30.

The stock witnessed a -11.79% loss in the last 1 month and extending the period to 3 months gives it a -3.70%, and is -3.90% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.99% over the week and 5.42% over the month.

Moderna Inc. (MRNA) has around 830 employees, a market worth around $26.76B and $105.80M in sales. Fwd P/E is 30.08. Distance from 52-week low is 379.53% and -31.86% from its 52-week high. The company has generated returns on investments over the last 12 months (-44.90%).

Moderna Inc. (MRNA) Analyst Forecasts

Moderna Inc. is expected to release its quarterly report on 11/04/2020 and quarterly earnings per share for the current quarter are estimated at -$0.41 with sales reaching $75.43M over the same period.The EPS is expected to shrink by -27.10% this year, but quarterly earnings will post 371.10% year-over-year. Quarterly sales are estimated to grow 310.80% in year-over-year returns.

Moderna Inc. (MRNA) Top Institutional Holders

298 institutions hold shares in Moderna Inc. (MRNA), with 94.47M shares held by insiders accounting for 23.94% while institutional investors hold 70.38% of the company’s shares. The shares outstanding are 380.53M, and float is at 315.89M with Short Float at 8.61%. Institutions hold 53.53% of the Float.

The top institutional shareholder in the company is Flagship Pioneering Inc. with over 39.87 million shares valued at $2.56 billion. The investor’s holdings represent 10.10% of the MRNA Shares outstanding. As of Jun 29, 2020, the second largest holder is FMR, LLC with 37.53 million shares valued at $2.41 billion to account for 9.51% of the shares outstanding. The other top investors are Vanguard Group, Inc. (The) which holds 25.63 million shares representing 6.49% and valued at over $1.65 billion, while Blackrock Inc. holds 5.02% of the shares totaling 19.82 million with a market value of $1.27 billion.

Moderna Inc. (MRNA) Insider Activity

A total of 476 insider transactions have happened at Moderna Inc. (MRNA) in the last six months, with sales accounting for 414 and purchases happening 62 times. The most recent transaction is an insider sale by Bancel Stephane, the company’s Chief Executive Officer. SEC filings show that Bancel Stephane sold 18,824 shares of the company’s common stock on Aug 20 at a price of $67.80 per share for a total of $1.28 million. Following the sale, the insider now owns 7.79 million shares.

Moderna Inc. disclosed in a document filed with the SEC on Aug 19 that Bancel Stephane (Chief Executive Officer) sold a total of 9,000 shares of the company’s common stock. The trade occurred on Aug 19 and was made at $66.74 per share for $0.6 million. Following the transaction, the insider now directly holds 6.7 million shares of the MRNA stock.

Still, SEC filings show that on Aug 17, Zaks Tal Zvi (Chief Medical Officer) disposed off 20,000 shares at an average price of $69.06 for $1.38 million. The insider now directly holds 0 shares of Moderna Inc. (MRNA).

Get The Best Stocks To Trade Every Day!

Join now to get the pre-market morning brief 100% free